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Objective: The aim of the study was to evaluate the effect of azithromycin on the expansion rate of small abdominal aortic
aneurysms (AAAs), and to determine whether or not a correlation exists between serological markers for Chlamydophilia
pneumonia (Cpn) infection and AAA expansion.
Methods: Nine vascular centers were included and 259 patients were invited to participate. Ten patients declined and 2
patients had chronic kidney failure, leaving a total of 247 patients. Inclusion criteria were: AAA 35-49 mm and age <80
years. Patients were randomized to receive either azithromycin (Azithromax, Pfizer Inc, New York, NY) 600 mg once
daily for 3 days and then 600 mg once weekly for 15 weeks, or placebo in identical tablets. The ultrasound scans were
performed in a standardized way within a month before inclusion and every 6 months for a minimum follow-up time of
18 months. Cpn serology was analyzed in blood samples taken at inclusion and 6 months later. Serum was analyzed for
Cpn IgA and IgG antibodies by microimmunofluorescence (MIF). Computed tomography (CT) scans were done in 66
patients at inclusion and at 1 year for volume calculations.
Results: Thirty-four patients were excluded, ie, could not be followed for 18 months, 20 in the placebo group and 16 in
the active treatment group. A total of 211 patients had at least two measurements and all were analyzed in an
intention-to-treat analysis. Detectable IgA against Cpn was found in 115 patients and detectable IgG against Cpn in 160
patients. No statistically significant differences were found between the groups regarding median expansion rate
measured by ultrasound scan (0.22 cm/year, interquartile range [IQR]: 0.09 to 0.34 in the placebo group vs 0.22, IQR:
0.12 to 0.36 in the treatment group, P  .85). Volume calculation did not change that outcome (10.4 cm3/year in the
placebo group vs 15.9 cm3/year in the treatment group, P .61). No correlation was found between serological markers
for Cpn infection and the expansion rate. Patients taking statins in combination with acetylsalicylic acid (ASA) had
significantly reduced expansion rate compared to patients who did not take statins or ASA, 0.14 cm/year vs 0.27
cm/year, P < .001.
Conclusion: Azithromycin did not have any effect on AAA expansion. No correlation was found between serological
markers for Cpn and AAA expansion, indicating no clinical relevance for Cpn testing in AAA surveillance. However, a
significant reduction in AAA expansion rate was found in patients treated with a combination of ASA and statins. ( J Vasc
Surg 2009;50:23-9.)Small abdominal aortic aneurysms (AAAs) are char-
acterized by a massive inflammatory infiltrate in the
adventitia and media of the aneurysm wall.1 It has been
shown that there is a correlation between this infiltrate
and the expansion of AAAs.2 This process seems to have
a late onset, as AAA has a prevalence of 4-8% in men 65
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doi:10.1016/j.jvs.2008.12.048years of age and older. Chlamydophilia pneumonia (Cpn)
is a widespread pathogen and about 80% of men and 70%
of women have been infected by the age of 65-years-
old.3 The Cpn antigen has been found in the majority of
abdominal aortic tissues using immunohistochemical
(IHC) techniques.4,5 Moreover, Vink et al6 reported the
finding of Cpn by IHC at multiple locations in the
arterial system within the same individual. IgA is an
antibody with a short half-life,7 and high titers of this
isotype have been associated with persistent infections.8
Lindholt et al9 have suggested that expansion of AAA is
associated with increased titers of Cpn IgA antibody.
Studies on rabbits have shown that Cpn can induce
atherosclerosis and aortic dilatation, and that these le-
sions can be reversed by antibiotic therapy.10,11 Antibi-
otics have been reported to temporarily reduce AAA
expansion.12,13 In other studies, aspirin and statins have
been reported to inhibit the in vitro growth of Cpn in cell
cultures.14,15
23
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tissue, and higher antibody titers against Cpn in patients
operated for AAA as compared to age and gender
matched controls.5 Here we present a prospective random-
ized double-blind trial where azithromycin is compared to
placebo for effects on the expansion of small AAAs. An
ultrasound scan was used for all randomized patients and
computed tomography (CT) scans for a subgroup in order
to calculate aneurysmal volume. A possible correlation be-
tween Cpn antibodies and AAA expansion, as well as the
role of acetylsalicylic acid (ASA) and statins were also
studied.
PATIENTS AND METHODS
The study was a prospective randomized double-blind
intention-to-treat trial, running between 2002 and 2005.
Inclusion criteria were: AAA 35-49 mm, age 80 years.
Exclusion criteria: AAA 35 mm or AAA 50 mm, age
81 years, intolerance to macrolide antibiotics, creatinine
clearance 40 mL/minute, and medication with ergota-
mine. Included patients were both those who had previ-
ously been diagnosed with AAA and newly diagnosed
patients meeting the inclusion criteria. Patients were ran-
Fig 1.domized in a 1:1 proportion in blocks of four to receiveeither azithromycin (Azithromax, Pfizer Inc) 600 mg once
daily for 3 days and then 600 mg once weekly for 15 weeks,
or placebo in identical tablets. Pfizer AB (Sollentuna, Swe-
den), generously provided the study medication and
matching placebo. Randomization was done in a standard-
ized way at Kronans Droghandel (Moelnlycke, Sweden)
and themedication code was kept at theHospital Pharmacy
(Akademiska Hospital, Uppsala, Sweden). The code was
not revealed until all analyses and follow-up scans were
completed.
Nine vascular centers were included and 259 patients
were invited to participate. Ten patients declined and 2
patients could not be included because of chronic kidney
failure, leaving a total of 247 patients (Fig 1). Patients were
recruited from surveillance programs in each center and all
participants gave written consent.Medical history, smoking
habits at inclusion and after 18 months (by oral confes-
sion), heredity for AAA, and current medication were also
recorded. Blood was sampled for control of kidney func-
tion, and serum taken at inclusion and 6 months later was
stored at70°C until analyzed for antibodies toCpn. Each
patient kept a record of their study medication, and these
forms were collected at 6 months. Surgery was performed
profile.according to clinical practice at each center. An AAA was
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decided for surgical intervention using standard clinical
practices. The decision for intervention was based upon the
“last” ultrasound scan in the study; no additional ultra-
sound scan measurement was done. An operation was
considered as an endpoint.
All participating centers performed ultrasonography
scans in a standardized way. The widest anterior-posterior
diameter was measured in both axial and transverse angles.
An ultrasound scan was done within a month before inclu-
sion and every 6 months for a minimum follow-up time of
18 months.
CT scans were done in 66 patients at inclusion and at 1
year for volume calculations, using a Siemens Somatom
Volume Zoom (Siemens Medical Solutions, Erlangen,
Germany). Eight centers used Acuson Sequoia (Universal
Diagnostic Solutions, Oceanside, Calif), one used Siemens
Elegra and all used a 4 MHz probe. Each patient analysis
was run using either 3 or 5 mm slices. One experienced
person did the volume calculations using a Siemens Soma-
tom Workstation on one occasion.
Chlamydophilia pneumonia serology. All blood
samples were taken at the department of clinical chemistry
at each hospital. Sera were separated from erythrocytes
immediately and frozen at70°C until tested. All sera from
each patient were analyzed at the same testing occasion.
Cpn-antibodies were analyzed by microimmunofluores-
cence (MIF) using a previously standardized and optimized
technique and reagents.16,17 Sera were diluted 1:32 with
phosphate buffered saline (PBS), pH 7.4 and tested for IgG
and IgA antibodies using 21-well antigen slides with ele-
mentary bodies of C. psittaci, C. trachomatis, and C. pneu-
moniae in each test well (Thermobio Oy, Helsinki, Fin-
land). Sera found to be positive in screening dilutions for
IgG were re-diluted and tested in doubling dilutions. Sera
positive for IgA were first absorbed with GullSorb (Gull
Laboratories, Salt Lake City, Utah) to remove IgG, and
then tested in doubling dilutions. Serum dilutions were
incubated with antigen for 14 to 16 hours at 4°C. Slides
were washed thoroughly in three changes of PBS pH 7.4,
then incubated with fluorescein isothiocyanate (FITC)
conjugated rabbit anti-human IgG, IgA or IgM (Dako-
patts, BioPortfolio, Glostrup, Denmark) at 37°C for 30
minutes. Control sera with specified high and low titers
were used on each testing occasion and tests were accepted
only if the titers were within one dilution step of the
predeterminedmean titers for the respective quality control
sera. All tests were read using an Olympus model BX40F4
UV microscope (Olympus Optical Co, LTD, Tokyo,
Japan) with an 50 oil immersion lens and an 10 ocular
lens (total magnification 400) by an experienced micro-
biologist. All titers were reported as reciprocals, and all sera
from the same individuals were tested on the same antigen
slide on the same testing occasion.
Statistical analysis. The primary endpoint was the
expansion rate of the AAA. For the purpose of sample size
calculation, the standard error of the variable diameter in
mm was estimated to 3 mm and the measuring uncertainty/ 2 mm. This means that the root mean square error
(RMSE) would be approximately 13. The number of
measuring occasions would be a minimum of four. The
expected annual expansion rate was assumed to be 0.26
cm/year for the placebo group. With these assumptions,
100 patients in each group would be sufficient to have a
power of 80% to detect an annual difference of 0.5 mm in
expansion rate between the groups at a significance level of
0.05. Categorical variables were summarized by percent-
ages and counts and continuous variables by medians and
inter-quartile ranges (IQR). For each patient with at least
two measurements, the average expansion rate of the AAA
diameter was estimated through a linear regression model.
The distribution of the estimated slopes was subsequently
compared between groups using the Wilcoxon-Mann-
Whitney test. For IgA and IgG, an average change of the
Log2-level of the concentration was estimated in a similar
way with a linear regression model for each patient. The
number of patients with decreasing, unchanged, or increas-
ing levels was compared between groups using the 2 tests.
The primary objective was to compare azithromycin treat-
ment with placebo. All other analyses are to be seen as
hypothesis generating. All statistical analyses were done
using R version 2.5.1.18 There were no interim analyses.
Ethics. All patients gave written consent and the study
was approved by the Committee of Ethics of Uppsala
University as well as local Ethic Committees, Dno: 01-349,
Health Sciences Ethics Board, University of Alberta, Edm-
onton, Canada, and by the Swedish Medical Products
Agency, Dno: 151:1254/01. The trial was registered ac-
cording to the Law of Biological Samples Record, no. 543.
RESULTS
Two hundred thirteen patients could be followed for a
minimum of 18 months and 211 patients were measured at
least twice. Five patients stopped taking the study medicine
(2 in placebo and 3 in the active group). As this was an
intention-to-treat study, these patients were followed and
analyzed as they were randomized. Detectable IgA against
Cpn was found in 115 and detectable IgG against Cpn in
160 patients with sera taken at inclusion and 6 months. As
seen in Table I, the two groups were well balanced except
for the history of stroke where 18.7% had stroke in the
placebo group compared with 9.4% in the treatment group.
There were 101 patients (52 in the placebo group and 49 in
the treatment group) on low dose (75 mg) ASA, and 84
patients (43 in the placebo group and 41 in the treatment
group) were on statins (Table I).
As seen in Table II and Fig 2, no statistically significant
differences were found between the groups regarding me-
dian expansion rate measured by ultrasound scan (0.22
cm/year; IQR, 0.09 to 0.34 in the placebo group vs 0.22;
IQR, 0.12 to 0.36 in the treatment group, P  .85).
Volume calculation, ie, the difference in median growth of
the volume, between 32 patients in the placebo group vs 34
in the treatment group, did not change that outcome:
(10.4 cm3/year in the placebo group vs 15.9 cm3/year in
the treatment group, P  .61). Individual growth rates
JOURNAL OF VASCULAR SURGERY
July 200926 Karlsson et alregarding gender, age, smoking habits, history of myocar-
dial infarction, previous stroke, asthma, chronic obstructive
pulmonary disease (COPD), heredity for AAA, previous
vascular operations, and hypertension are shown in Table
II. Patients on statins had a lower expansion rate than those
who did not: (0.16 vs 0.25 cm/year; P value, .008). In
addition, patients on ASA had lower expansion rates than
those not taking ASA (0.18 vs 0.26 cm/year; P value,
.004). Further analysis demonstrated that patients taking
statins in combination with ASA had significantly reduced
expansion rate compared to patients who did not take
statins or ASA, 0.14 cm/year vs 0.27 cm/year, P  .001
Table I. Baseline characteristics, 121 patients had
detectable IgA at one occasion and 172 patients had
detectable IgG on one occasion
N
Control
(n  107)
Treatment
(n  106)
N median (IQR) N median (IQR)
Age; years 213 71 (67, 76) 71 (67, 74)
Weight; kg 210 76.0 (70.0, 85.0) 79.5 (69.0, 89.0)
Height; cm 207 174 (169, 178) 174 (169, 181)
Gender: male 213 73.8 (79) 79.2 (84)
Previous MI 213 32.7 (35) 29.2 (31)
Previous stroke 213 18.7 (20) 9.4 (10)
Asthma 213 3.7 (4) 3.8 (4)
COPD 213 7.5 (8) 3.8 (4)
Current smoker 213 37.4 (40) 37.7 (40)
Smoking at 18
months 68 89.7 (35) 94.3 (33)
Package year 187 40 (30, 50) 40 (30, 50)
Heredity 211 13.3 (14) 13.2 (14)
Previous vasc. op 213 27.1 (29) 28.3 (30)
Adverse effect 212 7.5 (8) 12.4 (13)
Diabetes 213 3.7 (4) 4.7 (5)
Hypertension 213 57.0 (61) 60.4 (64)
Statin medication:
yes 213 40.2 (43) 39.6 (42)
ASA medication:
yes 212 48.6 (52) 46.7 (49)
Ultrasound: median
size 213 4.00 (3.60, 4.35) 4.00 (3.70, 4.40)
IgA:16 121 15.0 (9) 13.1 (8)
32 11.7 (7) 19.7 (12)
64 16.7 (10) 18.0 (11)
128 11.7 (7) 9.8 (6)
256 21.7 (13) 23.0 (14)
512 13.3 (8) 9.8 (6)
1024 5.0 (3) 4.9 (3)
2048 1.7 (1) 1.6 (1)
4096 3.3 (2) 0.0 (0)
IgG:32 172 11.4 (10) 4.8 (4)
64 5.7 (5) 10.7 (9)
128 19.3 (17) 11.9 (10)
256 13.6 (12) 22.6 (19)
512 29.5 (26) 27.4 (23)
1024 10.2 (9) 14.3 (12)
2048 2.3 (2) 3.6 (3)
4096 6.8 (6) 2.4 (2)
8192 1.1 (1) 2.4 (2)
kg, Kilograms; cm, centimeters; MI, myocardial infarction; COPD, chronic
obstructive pulmonary disease; vasc. op, vascular operation (does not include
CABG or PCI), IgA and IgG, antibody titers, all dilutions.(Table III).No correlation was found between serological markers
for Cpn infection and the expansion rate (Table IV). When
comparing the two groups, the distributions were similar
indicating that there was no difference in changes of IgA
levels over time. The majority of the patients had stable
IgA levels at subsequent visits. There was a trend towards
more patients who had a reduction in IgG levels in the
treatment group compared with patients in the placebo
group (Table IV).
Thirty-four patients were excluded, ie, could not be
followed for 18 months for the following reasons: 13
deaths, none of which were AAA-related (death certificates
were obtained from The Swedish National Board of Health
and Welfare regarding all patients that died during the
Table II. Summary of crude individual growth rates in
cm/year. N is the number of non-missing observations,
Med is the median, and Q1/Q3 is the lower and upper
quartiles, P values from the Wilcoxon-Mann-Whitney test
Subgroup N Q1 Med Q3 P value
Treatment
Treatment 105 0.12 0.22 0.36 .85
Control 106 0.01 0.22 0.34
Gender
Women 50 0.09 0.19 0.28 .216
Men 161 0.12 0.23 0.37
Age
 71 yrs 110 0.08 0.20 0.32 .118
 71 yrs 101 0.13 0.23 0.43
Smoking
No 132 0.08 0.22 0.36 .857
Yes 79 0.12 0.23 0.32
Prev MI
No 146 0.01 0.22 0.33 .826
Yes 65 0.10 0.22 0.38
Perestroika
No 182 0.09 0.22 0.36 .638
Yes 29 0.14 0.22 0.35
Asthma
No 203 0.10 0.22 0.35 .781
Yes 8 0.00 0.21 0.36
COPD
No 199 0.10 0.22 0.36 .337
Yes 12 0.08 0.20 0.28
Heredity
No 182 0.10 0.23 0.34 .831
Yes 27 0.08 0.21 0.40
Prev Vasc Surg
No 153 0.01 0.22 0.33 .370
Yes 58 0.10 0.26 0.38
Hypertension
No 87 0.09 0.22 0.34 .720
Yes 124 0.10 0.22 0.35
Statin
No 127 0.13 0.25 0.39 .008
Yes 84 0.06 0.16 0.32
ASA
No 110 0.13 0.26 0.40 .004
Yes 101 0.061 0.18 0.30
MI, Myocardial infarction; COPD, chronic obstructive pulmonary disease;
ASA, acetylsalicylic acid.study period). All deaths outside a hospital and deaths from
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hospital deaths were based on clinical information, 14 were
operated on for AAA (all but 1 with symptoms went to
surgery because of AAA size change), 2 could not be
reached for follow-up, 2 had AAA49mm and should not
have been included, 1 had an iliac aneurysm but no AAA, 1
had a disabling stroke, and 1 had a myocardial infarction
and did not want further follow-up (Fig 1). The total study
Fig 2. Diameter by time, by treatment – all patients. Lines show
smoothed (based on the Lowess method) estimates of the relation.
Table III. Growth rates in cm/year, for patients not
taking statins or ASA, statins or ASA separately, or in
combination. N is the number of patients, Med is the
median, and Q1/Q3 is the lower and upper quartiles
N Q1 Med Q3
Neither statins nor ASA 84 0.17 0.27 0.40
Only statins 27 0.08 0.23 0.38
Only ASA 44 0.10 0.19 0.31
Satins and ASA 57 0.04 0.14 0.30
ASA, acetylsalicylic acid.
Table IV. Changes in Cpn antibody-titers correlated to
placebo vs active drug and ASA medication
Subgroup
Decreasing Unchanged Increasing
N (%) N (%) N (%)
IgA
Control 15 (27.3) 32 (58.2) 8 (14.5)
Treatment 17 (28.3) 34 (56.7) 9 (15)
ASA No 13 (21.3) 36 (59) 12 (19.7)
ASA Yes 19 (35.2) 30 (55.6) 5 (9.3)
IgG
Control 15 (19.2) 55 (70.5) 8 (10.3)
Treatment 22 (26.8) 54 (65.9) 6 (7.3)
ASA No 17 (21.8) 56 (71.8) 5 (6.4)
ASA Yes 20 (24.4) 53 (64.6) 9 (11)
Cpn, Chlamydophilia pneumonia; ASA, acetylsalicylic acid.period was 36 months, and 29 patients were operated onfor AAA in the 18-36 month surveillance period; 13 in the
control group (1 with symptoms, 13 due to size change)
and 16 in the active treatment group (1 with symptoms, 1
with rupture, and 14 due to size change).
Twenty-one patients, 8 in the control group and 13 in
the active group reported side effects. All patients in the
control group had gastrointestinal side effects and 2
stopped taking the medication. In the group with active
substance, 3 stopped taking the study medication; 1 due to
diarrhea, 1 due to arthralgia, and 1 who had an allergic
reaction which initially was thought to be caused by study
medication but turned out to be a reaction to antihyper-
tensive medication. No patient reported taking other anti-
biotics while taking the study medication.
DISCUSSION
The aim of the present study was to evaluate the effect
of azithromycin on the expansion rate of small AAAs, and
to determine whether or not a correlation exists between
serological markers for Cpn infection and AAA expansion.
We have previously reported the presence of viableCpn
in the majority of tissue samples taken at their operation
from the anterior wall of AAAs; a high proportion of these
patients were found to have elevated specific IgG and/or
IgA antibody titers, which could indicate chronic infection
as compared to a control population.5 Lindholt et al9
reported that the expansion of AAA was related to the Cpn
IgA antibody titer. Moreover, Tambiah et al11,19 reported
that Cpn caused dilatation of the aorta in an animal model
and azithromycin prevented that process. Azithromycin is a
macrolide with efficacy against Cpn, it achieves high tissue
concentrations, has a long half-life, and is well tolerated by
patients.20 Azithromycin may also exert anti-inflammatory
activities,21 and it is reported to reduce of Cpn IgA titers
after treatment with azithromycin.8
Cpn is a common cause of acute and chronic respiratory
tract infections, although most of the infections result only
in mild clinical symptoms,22 and might, therefore, not be
diagnosed or treated with antibiotic, leaving Cpn infection
“free” to initiate chronic/persistent damage. Furthermore,
Cpn can infect and propagate in endothelial cells and
smooth muscle cells of aorta.23 A chronic persistent infec-
tion in macrophages, endothelial cells, and smooth muscle
cells can result in increased cytokine levels, and probably
also in immune complex deposition, leading to a collection
of lipids, macrophages, and thrombus. Human heat shock
protein 60 (HSP 60) is associated with atherosclerosis and
can provoke an autoimmune reaction.24 Chlamydial HSP
60 has close homology with and co-localizes with human
HSP 60 in macrophages, stimulating enhanced production
of MMP 9, an enzyme of vital importance in AAA patho-
genesis.2
Although antibiotics have been reported to temporarily
reduce AAA expansion12,13 we could not find any differ-
ence in expansion rate between the groups. Vammen et al13
used roxithromycin, also a macrolide that has the same
effect on Cpn as azithromycin. There are, however, some
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patients from surveillance programs, ie, included both gen-
ders and all ages under 81 years rather than a selected
screening cohort of men only, and we have twice as many
patients in each group. Vammen et al13 reported that 1/3
of the eligible patients did not give informed consent, in the
present study only 4% refused participation. Although
Vammen et al13 used only two persons to perform the
ultrasound scan, it was a strength of their study. The fact
that the two study groups are different when it comes to
gender and age distribution makes direct comparisons
somewhat difficult.
Several studies indicate that when Cpn comes into
contact with different agents such as tobacco smoke, anti-
biotics, or cytokines, a persistent phase is entered and the
organism is not detectable by culture. The inflammatory
reaction and subsequent aneurysmal formation might al-
ready be initiated despite Cpn entering a dormant, persis-
tent phase.25,26 We do not have data about penetration of
azithromycin in AAA tissue nor the optimal dose or treat-
ment length for this indication, however, we did use a
higher dose of antibiotics and 12 times longer treatment
periods compared to recommendations for community-
acquired pneumonia. According to this, we believe that our
choice of treatment regime is reasonable.
Smoking is a risk factor for AAA development and
expansion.27,28 Despite this, we could not detect any sta-
tistical difference in growth rate between smokers and
non-smokers. The percentage of smokers (37% in both
groups) is similar to the numbers reported in UK Small
Aneurysm Trial (UKSAT).29 MacSweeney et al28 reports a
difference in expansion rate between smokers vs non-smok-
ers. Forty-three patients in all were followed in that study,
and the difference in annual expansion rate was calculated
to be 0.07 cm per annum. Our result is based on 40
patients/group, and is at odds with prior studies.30,31 We
did not use urine-cotinine levels to confirm smoking, which
is a drawback in our study. The effect of smoking should
perhaps be addressed in a prospective study to clarify
doubts.
Statins in combination with ASA are commonly used
for cardiovascular patients, and patients with an AAA have
a high prevalence of coronary heart disease.32 Statins sup-
press the expansion of AAA33-35 via inhibition of MMP-9,
and may also suppress the development of experimental
AAA.15 It is, however, not clear whether this is a class effect
of statins. Subgroup analysis demonstrated that patients
taking statins had lower expansion rate than those who did
not take statins, and are in line with what Schlösser et al33
and Schouten et al34 report.
It was found that patients on ASA had lower expansion
rates compared with those not on ASA, indicating that ASA
might have a role in slowing AAA progression. High dose
ASA might also inhibit chlamydial growth.14 The results
were observed also after adjustment between those groups.
Statins and ASA have different anti-inflammatory proper-
ties, which might explain the complementary effect shown
in this study, although ASA seems to be more effective thanstatins (Table III). These results are remarkable but as they
are not primary endpoints they should be considered
hypothesis-generating only. However, it might indicate
that long-term medication with substances with anti-
inflammatory properties could slow expansion of AAAs,36
supporting inflammation as part of AAA pathogenesis. The
observation that statins and ASA may slow AAA expansion
warrants further study.
The fact that the placebo group had a higher percent-
age with earlier stroke than the antibiotic group may be a
confounding factor, as Cpn antibodies may be associated
with risk of stroke.37
The strength of this study is that it is a prospective
randomized double-blind investigation and we used not
only ultrasound scans for AAA measurement, but also
volume calculation with CT in a subgroup at inclusion and
after 1 year. As no modality could detect any difference
between the groups, we are comfortable with the results,
especially as volume calculation might reflect the “true”
expansion compared to ultrasound scan. This study can not
exclude Cpn as a participant in AAA pathogenesis, because
the damage could already be present, or Cpn might have
entered a persistent phase and, therefore, not be accessible
for antibiotic treatment.
We conclude that azithromycin treatment did not have
any effect on AAA expansion, and there was no correlation
between serological markers for Cpn activity and AAA
expansion, indicating no clinical relevance for C. pneu-
moniae testing in AAA surveillance.
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